1. Home
  2. GBIO vs KOSS Comparison

GBIO vs KOSS Comparison

Compare GBIO & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • KOSS
  • Stock Information
  • Founded
  • GBIO 2016
  • KOSS 1953
  • Country
  • GBIO United States
  • KOSS United States
  • Employees
  • GBIO N/A
  • KOSS N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • KOSS Consumer Electronics/Appliances
  • Sector
  • GBIO Health Care
  • KOSS Consumer Staples
  • Exchange
  • GBIO Nasdaq
  • KOSS Nasdaq
  • Market Cap
  • GBIO 64.8M
  • KOSS 62.5M
  • IPO Year
  • GBIO 2020
  • KOSS N/A
  • Fundamental
  • Price
  • GBIO $0.78
  • KOSS $6.33
  • Analyst Decision
  • GBIO Strong Buy
  • KOSS
  • Analyst Count
  • GBIO 2
  • KOSS 0
  • Target Price
  • GBIO $6.50
  • KOSS N/A
  • AVG Volume (30 Days)
  • GBIO 649.2K
  • KOSS 96.8K
  • Earning Date
  • GBIO 03-05-2025
  • KOSS 01-30-2025
  • Dividend Yield
  • GBIO N/A
  • KOSS N/A
  • EPS Growth
  • GBIO N/A
  • KOSS N/A
  • EPS
  • GBIO N/A
  • KOSS N/A
  • Revenue
  • GBIO $18,582,000.00
  • KOSS $12,289,961.00
  • Revenue This Year
  • GBIO $212.74
  • KOSS N/A
  • Revenue Next Year
  • GBIO N/A
  • KOSS N/A
  • P/E Ratio
  • GBIO N/A
  • KOSS N/A
  • Revenue Growth
  • GBIO 514.08
  • KOSS N/A
  • 52 Week Low
  • GBIO $0.72
  • KOSS $2.27
  • 52 Week High
  • GBIO $4.65
  • KOSS $18.73
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 29.26
  • KOSS 41.26
  • Support Level
  • GBIO $0.72
  • KOSS $5.69
  • Resistance Level
  • GBIO $1.00
  • KOSS $6.47
  • Average True Range (ATR)
  • GBIO 0.07
  • KOSS 0.35
  • MACD
  • GBIO -0.00
  • KOSS -0.04
  • Stochastic Oscillator
  • GBIO 18.68
  • KOSS 50.39

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.

Share on Social Networks: